14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
TAK vs ZTS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
TAK Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)
TAK Overall Winner
6-Pillar Tally: TAK 4 – 2 ZTS
Matrix Metrics: TAK 6 – 4 ZTS
As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Zoetis Inc. (ZTS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). TAK carries a Unified Composite Score of 47.7/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin), whereas ZTS carries 47.2/100 (HOLD) at $83.42 (13.1x Forward P/E, 37.9% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TAK vs ZTS. Trailing 12-month operating profitability (TAK 16.6% vs ZTS 37.9%) and valuation multiples (TAK 12.7x vs ZTS 13.1x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $67.5B market capitalization and 16.6% operating margin.
OpEx & R&D Reinvestment48.2% of Rev ($12.4B)
90D Engineering Disclosures0 Published
ZTS Moat ProfileHigh-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $33.7B market capitalization and 37.9% operating margin.
OpEx & R&D Reinvestment33.7% of Rev ($3.20B)
90D Engineering Disclosures0 Published
Investor FAQ TAK vs ZTS Key Questions & Quantitative Answers
As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Zoetis Inc. (ZTS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). TAK carries a Unified Composite Score of 47.7/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin), whereas ZTS carries 47.2/100 (HOLD) at $83.42 (13.1x Forward P/E, 37.9% operating margin). Technically, TAK sits in a Markup phase (RSI 73.1, UNCLASSIFIED options structure) and ZTS sits in a Markup phase (RSI 59.6, SURGE options structure).
TAK leads the Growth & Scale pillar: TAK posts +6.7% YoY revenue growth and -9.8% YoY earnings growth on $25.7B TTM revenue (64.8% gross margin, 16.6% operating margin), compared with ZTS at -1.3% YoY revenue growth and -11.8% YoY earnings growth on $9.49B TTM revenue (71.6% gross margin, 37.9% operating margin). On trailing 12-month operating scale, TAK generates $25.7B in USD-normalized revenue versus $9.49B for ZTS. In operating R&D and SG&A reinvestment, TAK deploys 48.2% of Rev ($12.4B) (0 90-day corporate R&D disclosures) versus 33.7% of Rev ($3.20B) (0 disclosures) for ZTS.
TAK screens cheaper on headline valuation multiples. TAK trades at 12.7x Forward P/E, N/M Trailing P/E, 0.47x PEG, and 2.6x EV/Revenue (29.1% EBITDA margin), whereas ZTS trades at 13.1x Forward P/E, 14.1x Trailing P/E, 15.37x PEG, and 4.4x EV/Revenue (24.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TAK (0.6% ROE) versus ZTS (57.6% ROE) capital efficiency.
In options market volatility and institutional positioning, TAK carries 22.4% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 22% Vol realized risk). By comparison, ZTS carries 43.4% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.17x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (0.53β · 49% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.